Advertisements


Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition

Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020......»»

Category: topSource: marketwatchDec 3rd, 2019

$4.3B deal delayed again: Roche extends Spark Therapeutics offer for sixth time

The slow-moving regulatory review process is once again being blamed for the latest delay in Roche’s proposed $4.3 billion acquisition of Philadelphia gene therapy pioneer Spark Therapeutics Inc. Roche said on Monday it is extending the offering per.....»»

Category: topSource: bizjournalsSep 3rd, 2019

Astellas bets $3 billion in gene therapy deal

Shares of Astellas Pharma Inc. rose about 1% in premarket trading after the Japanese drugmaker said Monday evening that it plans to acquire Audentes.....»»

Category: topSource: marketwatchDec 3rd, 2019

FTC staff recommends approval of Roche deal for Spark: report

The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday......»»

Category: topSource: reutersOct 24th, 2019

Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

Roche has extended, yet again, its tender offer to Spark Therapeutics in connection with the proposed $4.3 billion purchase of the Philadelphia gene therapy pioneer. For those keeping track, this is the fifth time the companies announced a new deadl.....»»

Category: topSource: bizjournalsJul 31st, 2019

Roche, Spark push back takeover deadline in $4.3 billion deal

Swiss drugmaker Roche has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction and expects it to close this year......»»

Category: topSource: reutersJul 8th, 2019

Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion......»»

Category: topSource: marketwatchJun 17th, 2019

$4.8 billion deal for gene therapy pioneer Spark Therapeutics delayed once more

The finish line for their proposed $4.8 billion deal is proving to be quite elusive for Roche and Spark Therapeutics. The companies announced Monday they have have each received a request for additional information and documentary material from the F.....»»

Category: topSource: bizjournalsJun 10th, 2019

Roche"s $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition......»»

Category: topSource: reutersJun 10th, 2019

Roche says $4.3 billion Spark offer still on track for June completion

Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it......»»

Category: topSource: reutersApr 3rd, 2019

Roche bids $4.8B for Spark and its gene therapy

Roche Holding AG will buy Spark Therapeutics Inc. for $4.8 billion, a deal that will give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes......»»

Category: topSource: moneycentralFeb 25th, 2019

Roche bets $4.3 billionon Spark in gene therapy move

Roche Holding AG is to buy U.S.-based Spark Therapeutics in a $4.3 billion deal that will give the Swiss drugmaker a foothold in gene therapy. Ciara Lee reports......»»

Category: topSource: moneycentralFeb 25th, 2019

Astellas-Audentes Deal Likely to Ignite More Acquisitions

Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfoliosRelated Stocks: QURE, RARE, SRPT, ALPMY, BOLD, BMRN, SLBD, BIIB, NVS, RHHBY,.....»»

Category: blogSource: gurufocusDec 5th, 2019

Cleveland-Cliffs Shocks Investors With AK Steel Acquisition

Iron ore miner Cleveland-Cliffs will acquire steelmaker AK Steel in an all-stock deal valued at $1.1 billion. Investors are less than excited......»»

Category: blogSource: 247wallstDec 3rd, 2019

Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B

One of the leading Cambridge biotechs hoping to treat diseases by silencing the underlying genetic cause has signed a billion-dollar deal to develop a hepatitis B treatment.  Drug giant Roche will pay $200 million upfront and up to $1.47 billion i.....»»

Category: topSource: bizjournalsOct 31st, 2019

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue......»»

Category: topSource: reutersSep 3rd, 2019

Roche, Spark extend $4.3 billion takeover again, this time to September 3

Roche and Spark Therapeutics announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue......»»

Category: topSource: reutersJul 31st, 2019

As IBM’s $34 Billion Red Hat Acquisition Closes, Investors Unmoved

IBM's $34 billion acquisition of Red Hat closed Tuesday. Here's what IBM hopes to get from the deal......»»

Category: blogSource: 247wallstJul 9th, 2019

Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

Swiss drug giant Roche Holdings AG Basel ADR (OTC: RHHBY) has announced another delay in its proposed takeover of the gene therapy biotech Spark Therapeutics Inc (NASDAQ: ONCE). read more.....»»

Category: blogSource: benzingaJun 10th, 2019

The Wall Street Journal: Catalent to buy Paragon Bioservices in $1.2 billion gene-therapy-drug deal

Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according to people familiar with the matter, the latest deal in the emerging market for gene-therapy drugs......»»

Category: topSource: marketwatchApr 14th, 2019

Roche extends Spark offer after getting only 29 percent

Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting only 29.4 percent of Spark's shares in a tender originally due to end on Wednesday......»»

Category: topSource: reutersApr 3rd, 2019